Arcus Biosciences (RCUS) News Today $8.39 -0.73 (-8.00%) Closing price 03/25/2025 03:58 PM EasternExtended Trading$8.44 +0.05 (+0.66%) As of 03/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC) and Lexeo Therapeutics, Inc. (LXEO)March 25 at 5:57 PM | markets.businessinsider.comArcus Biosciences Announces New Employment Inducement GrantsMarch 25 at 4:35 PM | businesswire.comArcus Biosciences (NYSE:RCUS) Trading 3.6% Higher - Still a Buy?Arcus Biosciences (NYSE:RCUS) Trading 3.6% Higher - What's Next?March 21, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Buys New Shares in Arcus Biosciences, Inc. (NYSE:RCUS)Connor Clark & Lunn Investment Management Ltd. bought a new stake in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 64,043 shares of the company's stock, valued atMarch 21, 2025 | marketbeat.comArcus Biosciences (NYSE:RCUS) Hits New 1-Year Low - Should You Sell?March 20, 2025 | americanbankingnews.com4DTIL : Assessing Precision BioSciences: Insights From 4 Financial AnalystsMarch 19, 2025 | benzinga.comArcus Biosciences (NYSE:RCUS) Shares Gap Down - What's Next?Arcus Biosciences (NYSE:RCUS) Shares Gap Down - Here's WhyMarch 18, 2025 | marketbeat.comArcus Biosciences (NYSE:RCUS) Hits New 12-Month Low - Here's WhyArcus Biosciences (NYSE:RCUS) Reaches New 12-Month Low - Here's WhyMarch 18, 2025 | marketbeat.comBank of New York Mellon Corp Has $5.68 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS)Bank of New York Mellon Corp lifted its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 8.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 381,615 shares of the company's stock after purchasing an additional 30,290 shares durMarch 17, 2025 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Recommendation of "Buy" by AnalystsShares of Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) have received an average rating of "Buy" from the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, eight have issued a buyMarch 16, 2025 | marketbeat.comArcus Biosciences at Barclays Conference: Strategic Pipeline InsightsMarch 15, 2025 | uk.investing.comArcus Biosciences, Inc. (RCUS): Among Top Insider Purchases Last MonthMarch 14, 2025 | msn.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (RCUS), aTyr Pharma (ATYR) and Lyra Therapeutics (LYRA)March 14, 2025 | markets.businessinsider.comCantor Fitzgerald Has Positive View of RCUS FY2025 EarningsArcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Research analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for Arcus Biosciences in a note issued to investors on Tuesday, March 11th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings of ($3March 14, 2025 | marketbeat.com2seventy bio (TSVT) was downgraded to a Hold Rating at Leerink PartnersMarch 11, 2025 | markets.businessinsider.comArcus Biosciences (NYSE:RCUS) Reaches New 52-Week Low - Should You Sell?Arcus Biosciences (NYSE:RCUS) Reaches New 52-Week Low - Here's What HappenedMarch 11, 2025 | marketbeat.comArcus Biosciences (NYSE:RCUS) Sets New 52-Week Low - Time to Sell?Arcus Biosciences (NYSE:RCUS) Reaches New 1-Year Low - What's Next?March 6, 2025 | marketbeat.comArcus Biosciences (RCUS): Among Stocks With At Least $10 Million In Insider Spending RecentlyMarch 5, 2025 | insidermonkey.comArcus Biosciences (NYSE:RCUS) Stock Price Down 5.8% - Here's What HappenedArcus Biosciences (NYSE:RCUS) Shares Down 5.8% - Here's WhyMarch 5, 2025 | marketbeat.comMorgan Stanley Remains a Buy on Arcus Biosciences (RCUS)March 3, 2025 | markets.businessinsider.comInsider Buying: Arcus Biosciences Co-Founder Bought US$201k Of SharesMarch 2, 2025 | finance.yahoo.comArcus Biosciences (NYSE:RCUS) Shares Gap Up Following Insider Buying ActivityArcus Biosciences (NYSE:RCUS) Shares Gap Up After Insider Buying ActivityMarch 1, 2025 | marketbeat.comHC Wainwright Lifts Earnings Estimates for Arcus BiosciencesArcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Research analysts at HC Wainwright raised their Q1 2025 EPS estimates for Arcus Biosciences in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($1.12) pMarch 1, 2025 | marketbeat.comQ1 EPS Forecast for Arcus Biosciences Decreased by AnalystArcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Stock analysts at Leerink Partnrs cut their Q1 2025 earnings estimates for shares of Arcus Biosciences in a research note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst D. Graybosch now expects that the company will earMarch 1, 2025 | marketbeat.comQ1 Earnings Estimate for Arcus Biosciences Issued By WedbushArcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Stock analysts at Wedbush increased their Q1 2025 earnings per share estimates for shares of Arcus Biosciences in a research report issued to clients and investors on Tuesday, February 25th. Wedbush analyst R. Driscoll now forecasts that the comMarch 1, 2025 | marketbeat.comInsider Buying: Arcus Biosciences, Inc. (NYSE:RCUS) Director Buys 20,000 Shares of StockArcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) Director Yasunori Kaneko purchased 20,000 shares of the company's stock in a transaction on Thursday, February 27th. The shares were purchased at an average price of $10.06 per share, for a total transaction of $201,200.00. Following the purchase, the director now owns 28,400 shares in the company, valued at approximately $285,704. The trade was a 238.10 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.February 28, 2025 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) CEO Terry J. Rosen Buys 19,800 SharesArcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) CEO Terry J. Rosen acquired 19,800 shares of the business's stock in a transaction on Thursday, February 27th. The shares were bought at an average price of $10.18 per share, with a total value of $201,564.00. Following the completion of the transaction, the chief executive officer now directly owns 2,554,160 shares of the company's stock, valued at approximately $26,001,348.80. The trade was a 0.78 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.February 28, 2025 | marketbeat.comArcus Biosciences (RCUS) Gets a Hold from Bank of America SecuritiesFebruary 28, 2025 | markets.businessinsider.comArcus Biosciences, Inc. (NYSE:RCUS) Analysts Are Cutting Their Estimates: Here's What You Need To KnowFebruary 28, 2025 | finance.yahoo.comLeerink Partnrs Weighs in on RCUS Q1 EarningsArcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for shares of Arcus Biosciences in a report released on Wednesday, February 26th. Leerink Partnrs analyst D. Graybosch forecasts that the company will pFebruary 28, 2025 | marketbeat.comInsider Buying: Arcus Biosciences, Inc. (NYSE:RCUS) Director Acquires 20,000 Shares of StockFebruary 28, 2025 | insidertrades.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Arcus Biosciences (RCUS) and Certara (CERT)February 28, 2025 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Arcus Biosciences (RCUS)February 27, 2025 | markets.businessinsider.comHC Wainwright & Co. Upgrades Arcus Biosciences (RCUS)February 27, 2025 | msn.comArcus Biosciences (NYSE:RCUS) Issues Quarterly Earnings Results, Beats Estimates By $0.14 EPSArcus Biosciences (NYSE:RCUS - Get Free Report) issued its earnings results on Tuesday. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.17) by $0.14. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%.February 26, 2025 | marketbeat.comArcus Biosciences (NYSE:RCUS) Issues Earnings ResultsArcus Biosciences (NYSE:RCUS - Get Free Report) issued its earnings results on Tuesday. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%.February 26, 2025 | marketbeat.comArcus Biosciences to Participate in Two Upcoming Investor ConferencesFebruary 26, 2025 | businesswire.comArcus Biosciences (RCUS) Receives a Buy from BarclaysFebruary 26, 2025 | markets.businessinsider.comArcus Biosciences upgraded to Buy from Neutral at H.C. WainwrightFebruary 26, 2025 | markets.businessinsider.comArcus Biosciences (NYSE:RCUS) Upgraded to Buy at HC WainwrightHC Wainwright raised shares of Arcus Biosciences from a "neutral" rating to a "buy" rating and increased their target price for the company from $18.00 to $24.00 in a report on Wednesday.February 26, 2025 | marketbeat.comArcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline UpdateFebruary 26, 2025 | finance.yahoo.comArcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline UpdateFebruary 25, 2025 | businesswire.comArcus Biosciences (NYSE:RCUS) Hits New 12-Month Low - What's Next?Arcus Biosciences (NYSE:RCUS) Hits New 52-Week Low - Should You Sell?February 25, 2025 | marketbeat.comArcus Biosciences Inc (RCUS) Q4 2024: Everything You Need to Know Ahead of EarningsFebruary 25, 2025 | finance.yahoo.comArcus Biosciences Announces New Employment Inducement GrantsFebruary 24, 2025 | businesswire.comBiotechs Highlight 6 Stocks Insiders Are Buying NowFebruary 23, 2025 | 247wallst.comArcus Biosciences (NYSE:RCUS) Shares Gap Up - Should You Buy?Arcus Biosciences (NYSE:RCUS) Shares Gap Up - Time to Buy?February 22, 2025 | marketbeat.comHC Wainwright Forecasts Lower Earnings for Arcus BiosciencesArcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Analysts at HC Wainwright cut their FY2025 earnings per share estimates for shares of Arcus Biosciences in a research note issued on Tuesday, February 18th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($4.69) per sFebruary 22, 2025 | marketbeat.comWedbush Estimates Arcus Biosciences' Q1 Earnings (NYSE:RCUS)Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Research analysts at Wedbush raised their Q1 2025 EPS estimates for shares of Arcus Biosciences in a research report issued on Tuesday, February 18th. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of ($1.3February 22, 2025 | marketbeat.comWhat is Wedbush's Forecast for RCUS FY2029 Earnings?Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Wedbush issued their FY2029 EPS estimates for Arcus Biosciences in a report released on Tuesday, February 18th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of $3.03 per share for the year. Wedbush currently has a "February 21, 2025 | marketbeat.com Remove Ads Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address RCUS Media Mentions By Week RCUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RCUS News Sentiment▼0.030.70▲Average Medical News Sentiment RCUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RCUS Articles This Week▼66▲RCUS Articles Average Week Remove Ads Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ultragenyx Pharmaceutical News Today SpringWorks Therapeutics News Today Akero Therapeutics News Today Alvotech News Today Rhythm Pharmaceuticals News Today Merus News Today Crinetics Pharmaceuticals News Today Immunovant News Today Viking Therapeutics News Today Protagonist Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:RCUS) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RCUS Stock Free RCUS Stock Alerts